How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
about
Bending the Cost Curve in Cancer CareItraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancerWhen is cancer care cost-effective? A systematic overview of cost-utility analyses in oncologySurviving with lung cancer: medication-taking and oral targeted therapy.Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer.Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the FutureAnnual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.Evolution of costs of cancer drugs in a Portuguese hospital.Emerging trends in cancer care: health plans' and pharmacy benefit managers' perspectives on changing care models.Me, TooOral cancer therapy: policy implications for the uninsured and underinsured populations.Expensive cancer drugs: a comparison between the United States and the United Kingdom.A decision exercise to engage cancer patients and families in deliberation about Medicare coverage for advanced cancer care.Medical expenditures of adult cancer survivors aged <65 years in the United States.How to develop treatments for biologically heterogeneous "diseases".Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposingReducing cancer costs and improving quality through collaboration with payers: a proposal from the Florida society of clinical oncologyThe cost-effectiveness of biopharmaceuticals: a look at the evidence.The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls.A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors"Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance?International comparison of the factors influencing reimbursement of targeted anti-cancer drugs.A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotypingAntiangiogenic therapy for breast cancerWhat is the role of maintenance therapy in the treatment of non-small cell lung cancer?Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Response to Michael Wonder's comments on the article 'Assessment of the therapeutic value of new medicines marketed in Australia'Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?Photodynamic therapy of cancer: an updateTherapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Cancer care burden: aiming at the Achilles heelHealth care costs: how do we decide value? When do we decide? How do we particularize the decisions?The economic pressures for biosimilar drug use in cancer medicineA chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.Drug rechallenge and treatment beyond progression--implications for drug resistance.Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.Personalized cancer medicine--advances and socio-economic challenges.Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
P2860
Q22248106-69CA1FA8-DDE3-4BC1-82D6-EDB35770D9E5Q24632703-80843800-65BE-4060-BD88-512B80DCEADAQ24645229-F6F610C3-637A-49C6-AEDE-D603BBC07D63Q30407705-79038D14-B88F-4370-BA7B-9478C4CB99AFQ30490454-091BEDB3-AA1A-41B3-9648-362C74747F14Q30843820-7B7131BA-A6F5-4011-9602-A6F80D70E15EQ30847275-D36D05C1-99D5-4D28-9DE2-1A2E0A902D45Q33585066-E38B35C7-17C0-4940-8CF4-E018A219BF99Q33714886-E1BFCAAC-5AA7-4582-8FE4-BD1047B316EBQ33866095-CED918DB-62C1-4FCE-AC8F-F677ED36D540Q33886089-8439F468-D0A7-4219-920B-763908A9D1D0Q33922623-F52EB499-9302-420D-B606-0B58CB33E229Q33957375-63C33FD0-D3FC-46C3-8599-77947C33D81CQ34013261-D079B89A-9B8D-4DBE-A931-CB89C78838BAQ34057001-2B6E187F-792E-44BD-AC22-F582DDD71E15Q34101536-71B0B941-8331-43EE-B4D8-D0274ACDEBBDQ34114926-587CD925-041E-4C3F-BB6D-548DFC539FA6Q34257719-9E28A232-F12C-4727-A0CB-56667C1905F1Q34310173-607F4EFA-CCF9-4868-B95F-B31922527592Q34450266-0F48ED44-4ADD-4A87-9387-EC6E9F60D030Q34483485-1FE1317D-AA32-4062-BED5-F4303E397939Q34608734-C183C136-9AD7-4D0B-AAC9-B6CA403EDD43Q34643295-66126EAC-93F7-4E1E-A90F-04739A8422D9Q34727967-032229F6-0398-4C8F-918C-A1979D2376A7Q34760933-A68903E1-4DC0-4B27-93F9-C5B112EC2A9CQ34989039-E8EA0CE0-CC65-48AD-ABFE-E36FBB587C9FQ35076269-FDD984EB-E4F4-4A2B-80FE-A06C2F6C7198Q35081379-2A80A4D8-AC17-4B11-9DCA-C18EEC95BC81Q35198442-A3327F19-2D14-4C06-AC9D-055E484D54C2Q35223735-CCE51404-952C-44B5-921F-43E9FB3C59C1Q35532394-EECE87F8-B28C-4A6F-8E4B-2637F1AEF533Q35584269-481461AC-065C-43B4-B28B-EE4C693BB52FQ35714571-A9C2C9CF-07BB-41D7-A3A9-ACCA6AF2B4BDQ35776197-2DB2DB7E-3EF7-4316-BA40-D6AA371F6587Q35795204-EFEB1FCE-743F-4853-9C52-861B91A651ABQ35837764-4DC6B072-6DFC-4086-AA86-C5F48669DB04Q35967416-279204B5-758B-417A-8501-949E3E90CFE6Q36001530-0B99A820-2DF4-4A77-984D-2A65CBA03920Q36213475-CE99D1CD-B877-497A-BC52-23D79ED6CD14Q36285594-1BD35774-9BF2-475F-B88E-23AFF98FAE7B
P2860
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How much is life worth: cetuxi ...... and the $440 billion question.
@en
How much is life worth: cetuxi ...... and the $440 billion question.
@nl
type
label
How much is life worth: cetuxi ...... and the $440 billion question.
@en
How much is life worth: cetuxi ...... and the $440 billion question.
@nl
prefLabel
How much is life worth: cetuxi ...... and the $440 billion question.
@en
How much is life worth: cetuxi ...... and the $440 billion question.
@nl
P2860
P356
P1476
How much is life worth: cetuxi ...... and the $440 billion question.
@en
P2093
P2860
P304
P356
10.1093/JNCI/DJP177
P407
P577
2009-06-29T00:00:00Z